Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma

The combination of CTLA-4 blockade ipilimumab (Ipi) with VEGF-A blocking antibody bevacizumab (Bev) has demonstrated favorable clinical outcomes in patients with advanced melanoma. Galectin-3 (Gal-3) plays a prominent role in tumor growth, metastasis, angiogenesis, and immune evasion. Here we report...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncoimmunology
Main Authors: Wu, Xinqi, Giobbie-Hurder, Anita, Connolly, Erin M., Li, Jingjing, Liao, Xiaoyun, Severgnini, Mariano, Zhou, Jun, Rodig, Scott, Hodi, F. Stephen
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5993498/
https://ncbi.nlm.nih.gov/pubmed/29900046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1440930
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki